Development of a Goal Attainment Scale (GAS) outcome measure for clinical interventional studies in paediatric autism.

The clinician cohort consisted only of psychiatrists and psychologists, excluding other disciplines like speech-language pathology or occupational therapy, which limits the generalizability of the measure's development to those fields. The study was a methodological development using qualitative interviews, not a validation trial. The measure has not been tested for reliability, validity, or sensitivity to change in an actual clinical trial setting. The sample size was small (40 participants), and the study was funded by a pharmaceutical company (Roche), which may influence the focus on endpoints suitable for drug trials rather than behavioral interventions. Intellectual disability status was not consistently confirmed via IQ testing for all participants, which may affect the interpretation of goal-setting capabilities in that subgroup.

The study was funded by Roche Products Ltd., which worked with the researchers on the design and manuscript. Several authors are employees or shareholders of Roche. Consulting fees were provided to the research organizations involved.

Do not assume this Goal Attainment Scale is ready for clinical use or has been validated for speech therapy outcomes. It was developed specifically for pharmaceutical trials by psychiatrists and psychologists, and the authors explicitly note that SLPs were not included in the development process.